Symptomatic Bone Metastases From Breast Cancer clinical trials

Explore recruiting symptomatic bone metastases from breast cancer clinical trials.

Also recruiting in Europe

Symptomatic Bone Metastases From Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Symptomatic Bone Metastases From Breast Cancer trials by city

Symptomatic Bone Metastases From Breast Cancer in Toronto Symptomatic Bone Metastases From Breast Cancer in Vancouver Symptomatic Bone Metastases From Breast Cancer in Montreal Symptomatic Bone Metastases From Breast Cancer in Calgary Symptomatic Bone Metastases From Breast Cancer in Edmonton Symptomatic Bone Metastases From Breast Cancer in Ottawa Symptomatic Bone Metastases From Breast Cancer in Winnipeg Symptomatic Bone Metastases From Breast Cancer in Quebec City Symptomatic Bone Metastases From Breast Cancer in Hamilton Symptomatic Bone Metastases From Breast Cancer in Kitchener Symptomatic Bone Metastases From Breast Cancer in London Symptomatic Bone Metastases From Breast Cancer in Halifax Symptomatic Bone Metastases From Breast Cancer in New York Symptomatic Bone Metastases From Breast Cancer in Los Angeles Symptomatic Bone Metastases From Breast Cancer in Chicago Symptomatic Bone Metastases From Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease